Israeli digital health startup UltraSight announced this week that it raised a $13 million Series B funding round to advance US clinical programs for its real-time, AI guidance for cardiac ultrasound in point-of-care settings. The Yozma Group Korea, Atain Specialty Insurance Company, and the Weizmann Institute of Science participated in the funding round.
Founded in 2019 and formerly called OnSight Medical, UltraSight developed an automated guidance system to bring the benefits of cardiac imaging to more healthcare professionals in new care settings, providing greater access to patients, the company says.
The company’s AI platform enhances sonography at the point of care, helping more patients be accurately diagnosed and treated. Point of care ultrasound allows medical professionals to diagnose patients wherever they are including clinics, community hospitals, ambulances and remote settings. Currently, cardiac sonography is a skill that takes years to acquire and requires daily practice to maintain high proficiency, creating a shortage in these highly specialized professionals.
UltraSight says it aims to change this dynamic by offering clinicians with no prior sonography training, automated guidance and quality assessment for conducting ultrasound scans.
“UltraSight provides a novel and versatile platform that addresses the unmet needs of patients and physicians,” said Davidi Vortman, CEO of UltraSight, in a company statement. “This financing round places us on the path to become a leading player in the ultrasound industry.”
“We are excited to help realize UltraSight’s mission,” said Wonjae Lee, Head of Asia Pacific, The Yozma Group. “UltraSight’s innovation is poised to reshape the ultrasound market and propel market growth.”